Eye Infections Global Market Report 2025

The eye infections market size has grown strongly in recent years. It will grow from $7.53 billion in 2024 to $7.96 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increased exposure to environmental pollutants causing eye irritations, a higher incidence of eye infections in children, rising medical tourism for eye surgeries, growing demand for combination therapies to treat complex infections, and a rise in allergic conjunctivitis cases.

The eye infections market size is expected to see strong growth in the next few years. It will grow to $9.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to the increasing prevalence of eye infections, the rising aging population prone to eye-related conditions, the growing impact of diabetes on eye health, the increasing cases of contact lens-related infections, and greater awareness about the importance of eye care. Major trends include advancements in diagnostic technologies, AI-powered diagnostic tools for eye infections, the integration of 3D printing technology in ophthalmic treatments, the development of genetically engineered therapies for rare eye infections, and the introduction of advanced antibiotics and antivirals.

The rising incidence and prevalence of eye-related disorders are expected to drive growth in the eye infections market. Eye-related disorders encompass a variety of conditions affecting the eyes, including diseases such as glaucoma, cataracts, macular degeneration, and refractive errors such as myopia and hyperopia. The increasing number of patients with these conditions is influenced by factors such as aging populations, lifestyle changes, environmental factors, and gaps in diagnostic capabilities that delay early detection. Eye infections can exacerbate or contribute to these disorders by causing inflammation, tissue damage, and weakening the eye’s natural defenses, potentially leading to complications such as vision loss or chronic conditions. For instance, in October 2024, the World Health Organization, a Switzerland-based health authority, reported that in 2023, 130,746 individuals underwent surgical treatment for advanced trachoma, while 32.9 million people received antibiotics, achieving a global coverage of 29%. As a result, the growing prevalence of eye-related disorders is expected to fuel expansion in the eye infections market.

Companies in the eye infections market are increasingly focusing on innovative therapies such as photodynamic therapy to improve treatment outcomes and minimize side effects. Photodynamic therapy involves using a light-sensitive drug activated by specific light wavelengths to selectively target and destroy infected or abnormal cells. For example, in December 2024, VisiRose Inc., a US-based clinical-stage biotechnology company, partnered with Provectus Biopharmaceuticals Inc., a US-based pharmaceutical firm, and Bascom Palmer Eye Institute, a US-based health center, to introduce Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT). This novel, non-invasive investigational treatment for infectious keratitis and other severe eye infections aims to address the growing global challenge of antimicrobial resistance (AMR) by offering a broad-spectrum ocular treatment. Designed to be safe, effective, and cost-efficient, this therapy meets the urgent need for innovative solutions in ophthalmology.

In July 2024, Merck And Co., Inc., a US-based science and technology company specializing in the development of medicines, vaccines, and health solutions, acquired EyeBio for $3 billion. This acquisition enables Merck to expand its ophthalmology pipeline and advance the development of innovative treatments for retinal diseases. Eyebiotech Limited, a UK-based biotechnology company, focuses on developing therapies for eye diseases.

Major players in the eye infections market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck And Co Inc, AbbVie Inc., Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Essilor International S.A., Teva Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc, Alcon Laboratories Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Carl Zeiss Meditec AG, Santen Pharmaceuticals Co Ltd, Rohto Pharmaceutical Co Ltd, Topcon Corporation, Akorn Pharmaceuticals, Alembic Pharmaceuticals Limited, Novaliq GmbH, Eyevance Pharmaceuticals LLC, Ocular Therapeutix, I-Med Pharma Inc., and EyeGate Pharmaceuticals Inc.

North America was the largest region in the eye infections market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in eye infections report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the eye infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Eye infections occur when harmful microorganisms such as bacteria, viruses, or fungi invade parts of the eye, causing inflammation, discomfort, and, in some cases, vision impairment. These infections can affect the eyelid, cornea, conjunctiva, or deeper eye structures, with common symptoms including redness, pain, discharge, swelling, and sensitivity to light. Since some eye infections are contagious, prompt medical treatment is essential to prevent complications.

The primary indications of eye infections include conjunctivitis, keratitis, endophthalmitis, blepharitis, stye, uveitis, cellulitis, and ocular herpes. Conjunctivitis, or pink eye, refers to the inflammation or infection of the conjunctiva, the thin, transparent tissue lining the inner eyelids and covering the white part of the eyeball. Treatment options generally consist of corticosteroids, quinolone antibiotics, macrolide antibiotics, tetracycline antibiotics, and polyene antifungals. These medications are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The eye infections market research report is one of a series of new reports that provides eye infections market statistics, including the eye infections industry global market size, regional shares, competitors with the eye infections market share, detailed eye infections market segments, market trends, and opportunities, and any further data you may need to thrive in the eye infections industry. This eye infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The eye infections market consists of sales of antibiotics, antifungal drugs, antiviral drugs, steroid eye drops, and surgical interventions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.